Personalized prostate cancer screening: improving PSA tests with genomic information
- PMID: 21160075
- DOI: 10.1126/scitranslmed.3001861
Personalized prostate cancer screening: improving PSA tests with genomic information
Abstract
The use of a prostate-specific antigen (PSA) test to screen for prostate cancer is controversial because of its modest predictive value and the potential overdiagnosis and over-treatment of the disease. A research article in this issue of Science Translational Medicine describes single-nucleotide polymorphisms (SNPs) in or near six genes that are independently associated with serum PSA concentrations and that help to explain interindividual PSA variation. Three of these SNPs are also associated with prostate biopsy outcomes. These findings are an important step toward incorporating genetic markers into PSA screening, with the ultimate goal of devising personalized PSA tests for use in the clinic.
Comment on
-
Genetic correction of PSA values using sequence variants associated with PSA levels.Sci Transl Med. 2010 Dec 15;2(62):62ra92. doi: 10.1126/scitranslmed.3001513. Sci Transl Med. 2010. PMID: 21160077 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous